Non-Specific Hemostatic Agents (PCC, aPCC, rVIIa) for Reversal of Direct Oral Anticoagulant Effect in Patients with Major Bleeding Complications: A Retrospective Review

Abstract Direct oral anticoagulants (DOACs) are used for the prevention and treatment of thromboembolism in a variety of clinical settings. Although rates of DOAC-associated major bleeding are similar to, or lower than that of warfarin, there are currently no antidotes available to reverse DOAC anticoagulant effect. In the absence of specific reversal agents a variety of strategies have evolved to overcome DOAC-induced …